Regulus Therapeutics reported $7.18M in Operating Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Alnylam Pharmaceuticals ALNY:US $ 416.5M 56.51M
AstraZeneca AZN:LN 840.42B 39.99B
Astrazeneca AZN:US 10.23B 280M
Biogen BIIB:US $ 2648.2M 727.1M
Celldex Therapeutics CLDX:US $ 36.56M 13.13M
Gilead Sciences GILD:US $ 4231M 2162M
GlaxoSmithKline GSK:LN 584.8B 95.1B
Intercept Pharmaceuticals ICPT:US $ 85.12M 13.73M
Intrexon XON:US $ 27.07M 22.84M
Lexicon Pharmaceuticals LXRX:US 24.04M 625K
Ligand Pharmaceuticals LGND:US $ 57.89M 4.39M
Merk MRK:US $ 9666M 666M
Omeros OMER:US $ 37.44M 2.39M
Regulus Therapeutics RGLS:US $ 7.18M 606K
Sangamo Biosciences SGMO:US $ 75.11M 1.62M
Spectrum Pharmaceuticals SPPI:US $ 25.39M 11.33M
Takeda 4502:JP 821.95B 52.96B
Vital Therapies VTL:US $ 20.61M 825K
YTE INCY:US $ 656.97M 40.27M